Jason Edward Brittain

Title: Jason Edward Brittain: Innovator in Pharmaceutical Development

Introduction

Jason Edward Brittain is a notable inventor based in El Cajon, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target respiratory and inflammatory diseases. With a total of nine patents to his name, Brittain's work has the potential to impact the treatment of various medical conditions.

Latest Patents

Among his latest patents is the DP2 antagonist, which is described as 2-(3-(2-((tert-butylthio)methyl)-4-(2,2-dimethyl-propionylamino)phenoxy)-4-methoxyphenyl)acetic acid, or a pharmaceutically acceptable salt thereof. This patent outlines methods for preparing the DP2 antagonist and pharmaceutical compositions suitable for administration to mammals. These compositions are intended for treating respiratory diseases, allergic conditions, and inflammatory diseases, as well as other conditions mediated by prostaglandin D. Another significant patent is for a similar DP2 antagonist, [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, which also includes methods of preparation and therapeutic applications.

Career Highlights

Jason Brittain has worked with several prominent companies in the pharmaceutical industry, including Cephalon, Inc. and Brickell Biotech, Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Brittain has collaborated with notable professionals in the field, including Joe Craig Franklin and Christopher David King. These collaborations have likely enhanced his research and development efforts.

Conclusion

Jason Edward Brittain is a distinguished inventor whose work in pharmaceutical innovation has the potential to improve treatment options for various diseases. His contributions through multiple patents reflect his commitment to advancing medical science.